TY - JOUR
T1 - Head and neck sweat gland adenocarcinoma
T2 - A population-based perspective of a rare entity
AU - Unsal, Aykut A.
AU - Patel, Varesh R.
AU - Chung, Sei Y.
AU - Zhou, Albert H.
AU - Baredes, Soly
AU - Eloy, Jean Anderson
N1 - Publisher Copyright:
© 2017 The American Laryngological, Rhinological and Otological Society, Inc.
PY - 2017/12
Y1 - 2017/12
N2 - Objectives: Head and neck sweat gland adenocarcinoma (HNSGA) is an extremely rare malignancy. We present the first population-based analysis regarding this entity. Study Design: Retrospective population-based analysis. Methods: Using the Surveillance, Epidemiology, and End Results registry from 2000 to 2013, we extracted 627 cases of HNSGA. Data were analyzed for incidence trends, demographic and clinicopathologic traits, and predictors of disease-specific survival (DSS). Results: The majority HNSGA cases were white, male, and 60 to 79 years old. The incidence was 0.036 per 100,000 people. Tumors most often presented as localized disease and histological grade II/III. The skin of the face was the most common primary site (43.4%), followed by the scalp and neck (31.6%). Overall 5-, 10-, and 20-year DSS were 94.6%, 89.6%, and 79.8%, respectively. Ethnicity did not affect survival, whereas a younger age at diagnosis and female sex conferred an advantage at 10 years (P = 0.0386) and 5 years (P = 0.0191), respectively. The origin of the HNSGA (apocrine vs. eccrine) did not affect outcomes. Regional and distant disease predicted worse DSS at 5, 10, and 20 years (P = 0.0026, P < 0.001, P < 0.001, respectively). Compared to grade I/II disease, grade III/IV dramatically worsened 5-, 10-, and 20-year DSS (P = 0.0035, P < 0.0001, P = 0.0011, respectively). Scalp and neck HNSGA exhibited the poorest 20-year DSS compared to other primary sites (P = 0.0024). Conclusion: We present the largest cohort of HNSGA. Significant poor prognostic indicators include older age, higher tumor grade, greater extent of invasion, and primary site of the scalp or neck. Level of Evidence: 4. Laryngoscope, 127:2757–2762, 2017.
AB - Objectives: Head and neck sweat gland adenocarcinoma (HNSGA) is an extremely rare malignancy. We present the first population-based analysis regarding this entity. Study Design: Retrospective population-based analysis. Methods: Using the Surveillance, Epidemiology, and End Results registry from 2000 to 2013, we extracted 627 cases of HNSGA. Data were analyzed for incidence trends, demographic and clinicopathologic traits, and predictors of disease-specific survival (DSS). Results: The majority HNSGA cases were white, male, and 60 to 79 years old. The incidence was 0.036 per 100,000 people. Tumors most often presented as localized disease and histological grade II/III. The skin of the face was the most common primary site (43.4%), followed by the scalp and neck (31.6%). Overall 5-, 10-, and 20-year DSS were 94.6%, 89.6%, and 79.8%, respectively. Ethnicity did not affect survival, whereas a younger age at diagnosis and female sex conferred an advantage at 10 years (P = 0.0386) and 5 years (P = 0.0191), respectively. The origin of the HNSGA (apocrine vs. eccrine) did not affect outcomes. Regional and distant disease predicted worse DSS at 5, 10, and 20 years (P = 0.0026, P < 0.001, P < 0.001, respectively). Compared to grade I/II disease, grade III/IV dramatically worsened 5-, 10-, and 20-year DSS (P = 0.0035, P < 0.0001, P = 0.0011, respectively). Scalp and neck HNSGA exhibited the poorest 20-year DSS compared to other primary sites (P = 0.0024). Conclusion: We present the largest cohort of HNSGA. Significant poor prognostic indicators include older age, higher tumor grade, greater extent of invasion, and primary site of the scalp or neck. Level of Evidence: 4. Laryngoscope, 127:2757–2762, 2017.
KW - SEER
KW - Surveillance, Epidemiology, and End Results
KW - Sweat gland adenocarcinoma
KW - apocrine adenocarcinoma
KW - eccrine adenocarcinoma
KW - head and neck cancer
KW - head and neck sweat gland adenocarcinoma
KW - incidence
KW - population-based
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85017650004&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017650004&partnerID=8YFLogxK
U2 - 10.1002/lary.26593
DO - 10.1002/lary.26593
M3 - Article
C2 - 28397272
AN - SCOPUS:85017650004
SN - 0023-852X
VL - 127
SP - 2757
EP - 2762
JO - Laryngoscope
JF - Laryngoscope
IS - 12
ER -